Chua Terence C, Yan Tristan D, Morris David L
Department of Surgery, University of New South Wales, St George Hospital, Kogarah, Sydney, NSW, Australia.
J Surg Oncol. 2009 Feb 1;99(2):109-13. doi: 10.1002/jso.21177.
Peritoneal mesothelioma is a rapidly progressing malignancy with a median survival of 6-12 months. Palliative surgery, chemotherapy and radiotherapy are futile and have not shown to improve survival. This paper reports the outcomes of cytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of this disease.
An observational study of 20 patients with peritoneal mesothelioma treated with CRS and HIPEC at the St George Hospital, Sydney, Australia. Survival analysis was performed using the Kaplan-Meier method and comparison using the Log Rank test.
There were six females. The mean age was 55.7 (9.0) years. The median survival was 29.5 (0.46-87.2) months with 1- and 3-year survival of 78.2% and 46.3%, respectively. Survival was found to be influenced by completeness of cytoreduction (P = 0.02) and histological subtype (P = 0.01). Patients with epitheloid peritoneal mesothelioma who had a CC0 had a median survival of 87.2 months.
CRS and HIPEC is a treatment option for peritoneal mesothelioma. Patients with epithelioid tumor who undergo complete cytoreduction may potentially benefit from this procedure.
腹膜间皮瘤是一种进展迅速的恶性肿瘤，中位生存期为6至12个月。姑息性手术、化疗和放疗均无效，且未显示能提高生存率。本文报告了细胞减灭术（CRS）和腹腔内热灌注化疗（HIPEC）治疗该疾病的结果。
对澳大利亚悉尼圣乔治医院20例接受CRS和HIPEC治疗的腹膜间皮瘤患者进行观察性研究。采用Kaplan-Meier方法进行生存分析，并使用对数秩检验进行比较。
有6名女性。平均年龄为55.7（9.0）岁。中位生存期为29.5（0.46 - 87.2）个月，1年和3年生存率分别为78.2%和46.3%。发现生存受细胞减灭的彻底性（P = 0.02）和组织学亚型（P = 0.01）影响。上皮样腹膜间皮瘤且达到CC0的患者中位生存期为87.2个月。
CRS和HIPEC是腹膜间皮瘤的一种治疗选择。接受彻底细胞减灭的上皮样肿瘤患者可能会从该手术中获益。
